A detailed history of Mai Capital Management transactions in Eli Lilly & CO stock. As of the latest transaction made, Mai Capital Management holds 99,652 shares of LLY stock, worth $77.6 Million. This represents 0.87% of its overall portfolio holdings.

Number of Shares
99,652
Previous 102,424 2.71%
Holding current value
$77.6 Million
Previous $92.7 Million 4.8%
% of portfolio
0.87%
Previous 0.94%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$772.14 - $960.02 $2.14 Million - $2.66 Million
-2,772 Reduced 2.71%
99,652 $88.3 Million
Q2 2024

Aug 12, 2024

BUY
$724.87 - $909.04 $2.38 Million - $2.98 Million
3,279 Added 3.31%
102,424 $92.7 Million
Q1 2024

May 08, 2024

BUY
$592.2 - $792.28 $3.26 Million - $4.37 Million
5,511 Added 5.89%
99,145 $77.1 Million
Q4 2023

Feb 09, 2024

BUY
$525.19 - $619.13 $1.12 Million - $1.32 Million
2,135 Added 2.33%
93,634 $54.6 Million
Q3 2023

Nov 14, 2023

SELL
$434.7 - $599.3 $703,779 - $970,266
-1,619 Reduced 1.74%
91,499 $49.1 Million
Q2 2023

Aug 02, 2023

BUY
$350.74 - $468.98 $33,320 - $44,553
95 Added 0.1%
93,118 $43.7 Million
Q1 2023

May 10, 2023

SELL
$310.63 - $364.82 $2.49 Million - $2.92 Million
-8,003 Reduced 7.92%
93,023 $31.9 Million
Q4 2022

Feb 09, 2023

SELL
$321.55 - $374.67 $3.58 Million - $4.17 Million
-11,135 Reduced 9.93%
101,026 $37 Million
Q3 2022

Nov 15, 2022

SELL
$296.48 - $337.87 $1.63 Million - $1.86 Million
-5,508 Reduced 4.68%
112,161 $36.3 Million
Q2 2022

Jul 19, 2022

BUY
$278.73 - $327.27 $1.17 Million - $1.37 Million
4,191 Added 3.69%
117,669 $38.2 Million
Q1 2022

May 10, 2022

BUY
$234.69 - $291.66 $102,559 - $127,455
437 Added 0.39%
113,478 $32.5 Million
Q4 2021

Feb 11, 2022

BUY
$224.85 - $279.04 $1.15 Million - $1.43 Million
5,132 Added 4.76%
113,041 $31.2 Million
Q3 2021

Nov 12, 2021

BUY
$221.6 - $272.71 $390,016 - $479,969
1,760 Added 1.66%
107,909 $24.9 Million
Q2 2021

Jul 19, 2021

SELL
$180.55 - $233.54 $2.68 Million - $3.46 Million
-14,816 Reduced 12.25%
106,149 $24.4 Million
Q1 2021

May 10, 2021

BUY
$164.32 - $212.72 $564,439 - $730,693
3,435 Added 2.92%
120,965 $22.6 Million
Q4 2020

Feb 16, 2021

BUY
$130.46 - $172.63 $13.9 Million - $18.4 Million
106,512 Added 966.71%
117,530 $19.8 Million
Q3 2020

Oct 26, 2020

SELL
$146.22 - $169.13 $19,008 - $21,986
-130 Reduced 1.17%
11,018 $1.63 Million
Q2 2020

Jul 27, 2020

SELL
$136.42 - $164.18 $26,738 - $32,179
-196 Reduced 1.73%
11,148 $1.83 Million
Q1 2020

Apr 16, 2020

BUY
$119.05 - $147.35 $322,863 - $399,613
2,712 Added 31.42%
11,344 $1.57 Million
Q4 2019

Feb 03, 2020

BUY
$106.92 - $132.43 $425,648 - $527,203
3,981 Added 85.59%
8,632 $1.13 Million
Q3 2019

Oct 29, 2019

BUY
$106.79 - $116.16 $16,338 - $17,772
153 Added 3.4%
4,651 $520,000
Q2 2019

Aug 15, 2019

SELL
$110.79 - $129.32 $123,087 - $143,674
-1,111 Reduced 19.81%
4,498 $498,000
Q1 2019

Apr 29, 2019

SELL
$111.31 - $131.02 $50,423 - $59,352
-453 Reduced 7.47%
5,609 $728,000
Q4 2018

Jan 30, 2019

BUY
$105.9 - $118.64 $38,971 - $43,659
368 Added 6.46%
6,062 $701,000
Q3 2018

Oct 12, 2018

SELL
$85.86 - $107.31 $23,783 - $29,724
-277 Reduced 4.64%
5,694 $611,000
Q2 2018

Aug 16, 2018

SELL
$75.7 - $86.88 $10,295 - $11,815
-136 Reduced 2.23%
5,971 $510,000
Q1 2018

Apr 17, 2018

BUY
$74.21 - $87.6 $6,827 - $8,059
92 Added 1.53%
6,107 $473,000
Q4 2017

Jan 30, 2018

BUY
$81.94 - $87.89 $9,750 - $10,458
119 Added 2.02%
6,015 $508,000
Q3 2017

Oct 12, 2017

SELL
$77.07 - $85.54 $4,547 - $5,046
-59 Reduced 0.99%
5,896 $504,000
Q2 2017

Aug 07, 2017

BUY
N/A
5,955
5,955 $490,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $740B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Mai Capital Management Portfolio

Follow Mai Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Mai Capital Management with notifications on news.